164 Long-term (four year) 28-joint count disease activity score (C-reactive protein) remission and improvements in skin disease with apremilast: phase III results from PALACE3
Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), C. Birbara(University of Massachusetts Chan Medical School), Jeffrey Crowley, Nikolay Delev(Bristol-Myers Squibb (Sweden)), Francisco J. Blanco(Complexo Hospitalario Universitario A Coruña), Maria Paris(Amgen (United States)), Lichen Teng(Harbin Medical University)
Cited by 0
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
|Annals of the Rheumatic Diseases|2013|668